Ironwood Pharmaceuticals shares surge 23.32% after-hours following Q3 earnings beat and raised 2025 revenue guidance.

Ironwood Pharmaceuticals (IRWD) surged 23.32% in after-hours trading following the release of strong Q3 2025 earnings results, which exceeded estimates, and an upward revision of full-year financial guidance. The company reported robust performance driven by increased U.S. net sales of LINZESS, its flagship GI drug, and recent regulatory milestones, including FDA approval of LINZESS for pediatric functional constipation. Additionally, the announcement of a revised Medicare net price for LINZESS, set at $136 for a 30-day supply effective 2027, aligned with management expectations, reinforcing pricing stability and long-term revenue visibility. These developments collectively bolstered investor confidence in the stock’s near-term profitability and pipeline progress, particularly for GLP-2 analogues targeting short bowel syndrome. The after-hours rally reflects optimism over sustained demand for LINZESS and the company’s strategic advancements in gastrointestinal therapeutics.